Market research
ARMP Armata Pharmaceuticals Inc
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 190M
- P/E ratio
- Not available
- Analyst target
- 17.5
- Dividend yield
- Not available
- Beta
- 1.33
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US04216R1023
- Market cap
- 190M
- P/E ratio
- Not available
- Analyst target
- 17.5
- Dividend yield
- Not available
- Beta
- 1.33
About
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARMP discussion.
5 years, 4 months ago
Armata Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 0.8% below its 200 day moving average.
From a valuation standpoint, the stock is 92.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 97.1.
Armata Pharmaceuticals Inc's total revenue rose by inf% to $504K since the same quarter in the previous year.
Its net income has dropped by 44.4% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 142.5% to $-7M since the same quarter in the previous year.
Based on the above factors, Armata Pharmaceuticals Inc gets an overall score of 2/5.